Study successfully achieved both primary and secondary objectives
ANAVEX®2-73 treatment resulted in improvements of all efficacy endpoints over 48 Weeks
Anavex plans to proceed to ANAVEX®2-73 pivotal trial for Parkinson’s disease
https://finance.yahoo.com/news/anavex-2-73-blarcamesine-shows-110000130.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.